antineoplastic agent, area under the curve, body surface, carboplatin, chromium 51, clinical practice, creatinine, creatinine clearance, disease severity, dose response, drug blood level, drug clearance, drug formulation, edetic acid, gynecologic cancer, human, kidney function, letter, practice guideline, priority journal, prospective study, unspecified side effect
dx.doi.org/10.1111/j.1525-1438.2007.01119.x, hdl.handle.net/1765/14851
International Journal of Gynecological Cancer
Erasmus MC: University Medical Center Rotterdam

de Jong, F.A, Verweij, J, & Sparreboom, A. (2008). Letter. International Journal of Gynecological Cancer, 18(5). doi:10.1111/j.1525-1438.2007.01119.x